UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial

Clinical therapeutics, 2007-02, Vol.29 (2), p.261-278

2007

Volltextzugriff (PDF)

A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II

Genetics in medicine, 2016-01, Vol.18 (1), p.73-81

2016

Volltextzugriff (PDF)

Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes (2077)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Efficacy and Safety of Apomorphine Sublingual Film for The Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Phase 3, Double-Blind, Placebo-Controlled Trial (P2.8-053)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD

Pulmonary therapy, 2021-12, Vol.7 (2), p.503-516

2021

Volltextzugriff (PDF)

ASSESSMENT OF PATIENT SYMPTOM AND FUNCTIONING OUTCOMES AMONG COPD SUBJECTS TREATED WITH ARFORMOTEROL OR RACEMIC FORMOTEROL: A 6-MONTH CLINICAL TRIAL

Chest, 2008-10, Vol.134 (4), p.16

2008

Volltextzugriff (PDF)

A phase II/III intrathecal enzyme replacement therapy clinical trial for MPS II patients with cognitive impairment

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.S83-S83

2016

Volltextzugriff (PDF)

Limited clinical impact of anti-idursulfase antibodies developed during long-term idursulfase enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) patients aged 5-35 years

Molecular genetics and metabolism, 2014-02, Vol.111 (2), p.S53-S53

2014

Volltextzugriff (PDF)

Long-term biomarker and cognitive follow-up of children with Hunter syndrome receiving intrathecal enzyme replacement therapy

Molecular genetics and metabolism, 2015-02, Vol.114 (2), p.S83-S83

2015

Volltextzugriff (PDF)

Investigational intrathecal (IT) enzyme replacement therapy for the severe form of Hunter syndrome (mucopolysaccharidosis type II, MPS II)

Molecular genetics and metabolism, 2014-02, Vol.111 (2), p.S79-S79

2014

Volltextzugriff (PDF)

LONG-TERM SAFETY AND EFFICACY OF NEBULIZED ARFORMOTEROL IN SUBJECTS WITH COPD

Chest, 2008-10, Vol.134 (4), p.106

2008

Volltextzugriff (PDF)

The Safety and Efficacy of Arformoterol and Formoterol in COPD

Chronic obstructive pulmonary disease, 2011-02, Vol.7 (1), p.17-31

2011

Volltextzugriff (PDF)

NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD: 348

Critical care medicine, 2006-12, Vol.34, p.A95

2006

Volltextzugriff (PDF)

Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials

Chronic obstructive pulmonary disease, 2008-02, Vol.5 (1), p.25-34

2008

Volltextzugriff (PDF)

BASELINE BODE CORRELATES WITH BDI AND BASELINE SGRG, BUT NOT WITH CHANGES IN THESE MEASURES FOLLOWING LABA TREATMENT IN TWO 12-WEEK DOUBLE-BLIND TRIALS

Chest, 2007-10, Vol.132 (4), p.521A-521A

2007

Volltextzugriff (PDF)

A Supported Education Program for Young Adults With Long-Term Mental Illness

Hospital & community psychiatry, 1991-08, Vol.42 (8), p.838-842

1991

Volltextzugriff (PDF)

NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD.: 348

Critical care medicine, 2006-12, Vol.34 (12 Abstract supplement), p.A95-A95

2006

Volltextzugriff (PDF)

A benefit-cost analysis of a supported employment model for persons with psychiatric disabilities

Evaluation and program planning, 1995-04, Vol.18 (2), p.105-115

1995

Volltextzugriff (PDF)

Discrete-time and ordinal logistic regression models for recurrent event data

Sciarappa, Kenneth Alan

1996

Volltextzugriff (PDF)

Secondary preventive medication persistence and adherence 1 year after stroke

Neurology, 2011-09, Vol.77 (12), p.1182

2011

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(19)
Dissertationen
(1)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial

A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II

Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes (2077)

Efficacy and Safety of Apomorphine Sublingual Film for The Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Phase 3, Double-Blind, Placebo-Controlled Trial (P2.8-053)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD

ASSESSMENT OF PATIENT SYMPTOM AND FUNCTIONING OUTCOMES AMONG COPD SUBJECTS TREATED WITH ARFORMOTEROL OR RACEMIC FORMOTEROL: A 6-MONTH CLINICAL TRIAL

A phase II/III intrathecal enzyme replacement therapy clinical trial for MPS II patients with cognitive impairment

Limited clinical impact of anti-idursulfase antibodies developed during long-term idursulfase enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) patients aged 5-35 years

Long-term biomarker and cognitive follow-up of children with Hunter syndrome receiving intrathecal enzyme replacement therapy

Investigational intrathecal (IT) enzyme replacement therapy for the severe form of Hunter syndrome (mucopolysaccharidosis type II, MPS II)

LONG-TERM SAFETY AND EFFICACY OF NEBULIZED ARFORMOTEROL IN SUBJECTS WITH COPD

The Safety and Efficacy of Arformoterol and Formoterol in COPD

NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD: 348

Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials

BASELINE BODE CORRELATES WITH BDI AND BASELINE SGRG, BUT NOT WITH CHANGES IN THESE MEASURES FOLLOWING LABA TREATMENT IN TWO 12-WEEK DOUBLE-BLIND TRIALS

A Supported Education Program for Young Adults With Long-Term Mental Illness

NEBULIZED ARFORMOTEROL, A LONG-ACTING β2 -ADRENERGIC BRONCHODILATOR, IN PATIENTS WITH COPD.: 348

A benefit-cost analysis of a supported employment model for persons with psychiatric disabilities

Discrete-time and ordinal logistic regression models for recurrent event data

Secondary preventive medication persistence and adherence 1 year after stroke

Suchergebnisse filtern